00643 1619351673.Pdf
Total Page：16
File Type：pdf, Size：1020Kb
Load more
Recommended publications
-
Antimicrobial Resistance and Disinfectants Susceptibility of Persistent Bacteria in a Tertiary Care Hospital
Journal of Microbiology and Antimicrobials Vol. 2(7), pp. xx-xx, October 2010 Available online http://www.academicjournals.org/JMA ISSN 2141-2308 ©2010 Academic Journals Full Length Research Paper Antimicrobial resistance and disinfectants susceptibility of persistent bacteria in a tertiary care hospital Maria Lucia Morcerf Bouzada1, Vania Lucia Silva1, Felipe Augusto Sa Moreira1, Girlene Alves Silva2 and Claudio Galuppo Diniz1* 1Department of Parasitology, Microbiology and Immunology, Laboratory of Bacterial Physiology and Molecular Genetics, Institute of Biological Sciences, Federal University of Juiz de Fora, Juiz de Fora/MG,36036-900, Brazil. 2Department of Applied Nursing, School of Nursing, Federal University of Juiz de Fora, Juiz de Fora/MG, 36036-900, Brazil. Accepted 22 October, 2010 It is well known that putative pathogenic bacteria are ubiquitous and widely distributed in the hospital environment. This study aimed to detect bacterial persistence in the nosocomial environment (different critical areas of the hospital) after mopping by the cleaning staff. Susceptibility patterns to antimicrobial drugs and disinfectants commonly used in health services were also investigated by disk diffusion and agar dilution tests. Rinse water from mops was processed for isolation of Enterobacteriaceae (GNR), non-fermenting Gram-negative rods (NFGNR), coagulase-negative staphylococci (CNS) and enterococci (ENT). Microorganisms were biochemically characterized and 547 strains were recovered. Only CNS and NFGNR were isolated in all critical areas. Overall 67% of the isolated bacteria were resistant to more than three drugs, being considered as multiresistant. Disinfectants were effective in concentrations ranging from 0.125 to 1%. Hospitals provide reservoirs of multiresistant microorganisms borne by patients and staff, but the hospital environment may be an important repository. -
Detailed Teacher Instructions: Inheritance, X-Linkage, Evolution Over Multiple Generations, Genetic Hitchhiking
Revised Laboratory on Molecular Evolution Gredler et al. (2015) Detailed Teacher Instructions: Inheritance, X-linkage, Evolution over Multiple Generations, Genetic Hitchhiking Objectives: Between the laboratory exercise and the associated lectures, students will be able to: Explain the process of evolution by natural selection in terms of fitness-related traits and allele frequencies Describe the concept of X-linked inheritance Perform DNA extractions, PCR, and gel electrophoresis Analyze molecular data as a means of understanding an evolutionary process Explain the concepts of selective sweeps, hitchhiking, and linkage Materials: Drosophila melanogaster heat shock white-eyed strain 60739 Drosophila melanogaster heat shock white-eyed strain 60740 Drosophila melanogaster Zimbabwe (wild type) strain 60741 Culture vials, plugs, and food (media) for Drosophila rearing Carolina Biological FlyNap® Anesthetic Kit: 173010 (Optional but strongly preferred) CO2 anesthetization facilities for Drosophila DNA extraction buffer and proteinase-K for DNA isolation Sorting brushes "Squishing buffer" and proteinase-K for DNA isolation Equipment and reagents for polymerase chain reaction including oligonucleotides for "NEAR" and "FAR" markers Equipment and reagents for agarose gel electrophoresis Magnifying glasses Sharpie markers Custom PowerPoints and projector, if desired 1 Revised Laboratory on Molecular Evolution Gredler et al. (2015) This exercise allows students to view evolution over multiple generations, experiment with molecular techniques, and learn concepts of molecular evolution. This exercise requires considerable advance preparation (must be started approximately 6 weeks before planned class start date, with initial white- eyed fly crosses starting approximately 4 weeks before the planned class start date). The supplies and directions are listed out so that you may purchase or use supplies you already have. -
Identification of Genes Involved in Acid Tolerance, Antimicrobial Resistance and Virulence of Enterococcus Faecium
Identification of genes involved in acid tolerance, antimicrobial resistance and virulence of Enterococcus faecium Thesis submitted by Hashimatul Fatma binti Hashim For the degree of DOCTOR OF PHILOSOPHY in the Faculty of Medical Sciences University College London Division of Microbial Diseases UCL Eastman Dental Institute 256 Gray’s Inn Road London WC1X 8LD UK 2016 Declaration I hereby certify that the work embodied in this thesis is the result of my own investigation, except where otherwise stated. 2 Abstract Enterococcus faecium is an opportunistic human nosocomial pathogen that has developed resistance to many existing antimicrobial therapies. Treatment of enterococcal infections is becoming increasingly challenging and there are limited therapeutic options against multidrug-resistant enterococci. The work described in this thesis aimed to identify genes involved in resistance to host stresses and virulence as these could potentially be future therapeutic targets. An E. faecium transposon mutant library was screened for altered resistance to lysozyme and to nisin as a model antimicrobial peptide. This approach led to the identification of several genes that contribute to lysozyme and nisin resistance. A number of mutants that were sensitive to nisin had a transposon insertion in a gene predicted to encode a tyrosine decarboxylase. It was shown that the tyrosine decarboxylase plays a role in acid tolerance and mediates virulence of E. faecium in a Galleria mellonella larvae infection model. A targeted genetic approach was used to examine the role of an E. faecium serine threonine protein kinase (Stk1) in antimicrobials resistance, host cell stresses and virulence. Disruption of the stk1 gene led to higher sensitivity to antibiotics that target the penicillin- binding proteins and bile salts compared to the wild type. -
Clinical Review Nicholas Rister, MD NDA 021572 Cubicin (Daptomycin for Injection)
Clinical Review Nicholas Rister, MD NDA 021572 Cubicin (Daptomycin for injection) CLINICAL REVIEW Application Type NDA supplement Application Number(s) 21572 Priority or Standard Priority Submit Date(s) March 1, 2017 Received Date(s) March 2, 2017 PDUFA Goal Date September 2, 2017 Division / Office DAIP/OAP Reviewer Name(s) Nicholas Rister, MD Review Completion Date August 4, 2017 Established Name Daptomycin (Proposed) Trade Name Cubicin Therapeutic Class Cyclic Lipopeptide Applicant Cubist Pharmaceuticals Formulation(s) Injection Dosing Regimen 7 mg/kg (12-17 years), 9 mg/kg (7-11 years), and 12 mg/kg (1-6 years) Indication(s) Bacteremia caused by Staphylococcus aureus Intended Population(s) Ages 1-17 years 1 Reference ID: 4142515 Clinical Review Nicholas Rister, MD NDA 021572 Cubicin (Daptomycin for injection) Table of Contents 1 RECOMMENDATIONS/RISK BENEFIT ASSESSMENT ......................................... 7 1.1 Recommendation on Regulatory Action ............................................................. 7 1.2 Risk Benefit Assessment .................................................................................... 7 1.3 Recommendations for Postmarket Risk Evaluation and Mitigation Strategies ... 8 1.4 Recommendations for Postmarket Requirements and Commitments ................ 8 2 INTRODUCTION AND REGULATORY BACKGROUND ........................................ 8 2.1 Product Information ............................................................................................ 8 2.2 Tables of Currently Available Treatments -
REPOSITORY of RESEARCH SYNOPSES for M.PHIL DEGREE PRESENTED to ASRB of UHS
REPOSITORY OF RESEARCH SYNOPSES FOR M.PHIL DEGREE PRESENTED To ASRB Of UHS Degree Student Name InstituteResearch Title Supervisor Report Status M.Phil Anatomy Dr Amer Qayum RMC Rawalpindi Morphology of human ascending aortic fold Prof. Tassaduq Hussain Sheikh Approved Dr. Ahmad Farzad M.Phil Anatomy UHS Lahore Effect of vitamin E on nephrotoxicity in methimazole induced hypothyroidism in albino mice Prof. Dr. Khalid Parvez Lone Approved Qureshi Dr. Aisha M.Phil Anatomy UHS Lahore Effect of Cinnamon bark oil on Cadmium induced testicular toxicity in adult male albino rats Prof. Dr. Muhammad Tahir Approved Muhammad Effect Of Citrullus colocynthis aqueous seed extract on beta cell regeneration and intra-islet M.Phil Anatomy Dr. Alia Amin UHS Lahore Prof. Dr. Muhammad Tahir Approved vasculature in alloxan induced diabetic male albino rats M.Phil Anatomy Dr. Alvia Batool PGMI Lahore Weight and histological changes induced by ribavirin in the testes of albino rats Prof. Dr. Fozia Farzana Approved The effects of Ficus carica L. (Anjir) leaf extract on gentamicin induced nephrotoxicity in adult M.Phil Anatomy Dr. Ammara Ghafoor UHS Lahore Prof. Dr. Khalid Parvez Lone Approved male albino mice Protective effect of aqueous extract of Carica papaya L. seeds on neproxen induced M.Phil Anatomy Dr. Ammara Riaz UHS Lahore Prof. Dr. Muhammad Tahir Approved nephrotoxicity in rats Histopathological effects of omeprazole on kidney of albino rats in different doses and M.Phil Anatomy Dr. Amna Mubeen PGMI Lahore Prof. Dr. Fozia Farzana Approved duration M.Phil Anatomy Dr. Aneeqa Chughtai UHS Lahore Anatomical variations of placentae in healthy pregnancies among local population Prof. -
Safety Data Sheet
SAFETY DATA SHEET SECTION 1: Identification of the substance/mixture and of the company/undertaking 1.1. Product identifier Name of the substance Sodium tungstate Identification number 13472-45-2 (CAS number) Synonyms SODIUM TUNGSTATE * Tungstic acid, Disodium salt Issue date 18-May-2015 Version number 02 Revision date 14-July-2015 Supersedes date 18-May-2015 1.2. Relevant identified uses of the substance or mixture and uses advised against Identified uses Not available. Uses advised against None known. 1.3. Details of the supplier of the safety data sheet Supplier Company name Materion Advanced Chemicals Inc. Address 407 N. 13th Street 1316 W. St. Paul Avenue Milwaukee, WI 53233 United States Division Milwaukee Telephone 414.212.0257 e-mail [email protected] Contact person Noreen Atkinson 1.4. Emergency telephone number SECTION 2: Hazards identification 2.1. Classification of the substance or mixture The substance has been assessed and/or tested for its physical, health and environmental hazards and the following classification applies. Classification according to Directive 67/548/EEC or 1999/45/EC as amended Classification Xn;R22, R52/53 The full text for all R-phrases is displayed in section 16. Classification according to Regulation (EC) No 1272/2008 as amended Health hazards Acute toxicity, oral Category 4 H302 - Harmful if swallowed. H302 - Harmful if swallowed. Environmental hazards Hazardous to the aquatic environment, Category 3 H412 - Harmful to aquatic life with long-term aquatic hazard long lasting effects. Hazard summary Physical hazards Not classified for physical hazards. Health hazards Harmful if swallowed. Occupational exposure to the substance or mixture may cause adverse health effects. -
IN a PACK SIZE of 100Ml 2 3,3 DIAMINOBENZIDINE TETRAHYDROCHLORIDE, in a PACK SIZE of 5Gm
Item NAME OF THE ITEM No. Group 1 Pathology 1 2 MERCAPTOETHANOL (2-ME), IN A PACK SIZE OF 100ml 2 3,3 DIAMINOBENZIDINE TETRAHYDROCHLORIDE, IN A PACK SIZE OF 5gm 3 A.P.T.T WITH CALCIUM CHLORIDE (LIQUID STABLE), IN A PACK SIZE OF 1 X 3ml 4 A.P.T.T WITH CALCIUM CHLORIDE (LIQUID STABLE), IN A PACK SIZE OF 1 X 4 ml 5 ACETIC ACID GLACIAL (AR), IN A PACK SIZE OF 2.5 LITRES 6 ACETIC ACID GLACIAL (AR), IN A PACK SIZE OF 500ml 7 ACETONE, IN A PACK SIZE OF 2.5 LITRES 8 ACETONE, IN A PACK SIZE OF 500ml 9 ACID FUSCHIN, IN A PACK SIZE OF 25gm 10 ACTIVATED CHARCOAL, 500 gm 11 AET (2-AMINOETHYL ISO THIOURANIUMBROMIDE) 100 gm 12 ALCIAN BLUE, IN A PACK SIZE OF 5gm 13 ALUMINIUM CHLORIDE ANHYDROUS, IN A PACK SIZE OF 500gm 14 ALUMINIUM HYDROXIDE, IN A PACK SIZE OF 500gm 15 ALUMINIUM SULPHATE 500gm 16 AMMONIUM FERROUS SULPHATE 500gm 17 AMMONIUM OXALATE, IN A PACK SIZE OF 500gm ANTI - A ANTISERA MONOCLONAL 18 AVIDITY - 3-4 SECONDS TITRE - 1:256 IN A PACK SIZE OF 6 X 10 ml ANTI - B ANTISERA MONOCLONAL 19 AVIDITY - 3-4 SECONDS TITRE - 1:256 , IN A PACK SIZE OF 6 X 10 ml ANTI - D Igm MONOCLONAL 20 AVIDITY - 5-10 SECONDS TITRE - 1:128 , IN A PACK SIZE OF 6 X 10 ml ANTI - D Igm + IgG BLEND 21 AVIDITY - 10-20 SECONDS TITRE - 1:256 IN A PACK SIZE OF 6 X 10 ml 22 APTT CONTROL , IN A PACK SIZE OF 12 X 1 ml 23 Aqueous Borax 125 ml Page 1 of 52 24 Borax Carmine Powder 25 gm 25 Ammonium Sulphate Crystals 500gm 26 BARIUM CHLORIDE (AR), IN A PACK SIZE OF 500gm 27 BASIC FUSCHIN, IN A PACK SIZE OF 25gm 28 BENEDICT'S REAGENT (QUALITATIVE), IN A PACK SIZE OF 5LITRES 29 BENZIDINE, IN A PACK SIZE OF 50gm 30 BIEBRICH SCARLET, IN A PACK SIZE OF 25gm 31 BRILLIANT CRESYL BLUE (POWDER), IN A PACK SIZE OF 25gm 32 BRILLIANT CRESYL BLUE (SOLN.), IN A PACK SIZE OF 100 ml 33 BROMELAINE Lowest Pack Size 34 CALCIUM CHLORIDE ANHYDROUS, IN A PACK SIZE OF 500gm. -
Quinupristin/Dalfopristin
Reprinted from www.antimicrobe.org Quinupristin/Dalfopristin Antibiotic Class: Streptogramin Antimicrobial Activity: Gram-positive bacteria. In-vitro data suggests streptogramins possess activity against gram-negative upper respiratory tract pathogens and gram-negative anaerobes. Mechanism of Action: Inhibition of mRNA translation by binding to the 50S subunit of bacterial ribosomes. Pharmacodynamics: Predominantly independent of concentration once above four times the MIC of common Staphylococci and Streptococci. Pharmacokinetics: (7.5mg/kg dose at steady state) Cmax: 3.2 and 7.96mg/L (quinupristin and dalfopristin respectively) Half-life: 3.07 and 1.04 hours (quinupristin and dalfopristin respectively) Volume of distribution: 0.45 and 0.24L/kg (quinupristin and dalfopristin respectively) Adverse Effects: Venous irritation due to quinupristin/dalfopristin is common. In comparative trials approximately 40% of patients experienced infusion site adverse reactions compared to 25% of comparator treated patients. Increasing the infusion volume or administering the drug via central line may attenuate this reaction. In two compassionate use studies, arthralgias (9.1%) and myalgias (6.6%) were the most common adverse event related to quinupristin/dalfopristin. Hyperbilirubinemia was documented in up to 25% of quinupristin/dalfopristin treated patients in compassionate use/non-comparative studies. Dosage: Intravenous only – available as 500mg (150mg quinupristin and 350mg dalfopristin) and 600mg (180mg quinupristin and 420mg dalfopristin) powder for reconstitution vials Serious or life-threatening infections associated with vancomycin-resistant Enterococcus faecium – 7.5mg/kg every 8 hours Complicated skin and skin structure infection caused by methicillin-susceptible S. aureus or S. pyogenes – 7.5mg/kg every 12 hours Disease state based dosing: Hepatic failure: Although no dosage official dosage adjustment recommendations exist, pharmacokinetic data in patients with hepatic cirrhosis (Childs-Pugh class A or B) suggest that dosage adjustments may be necessary. -
Hiper® Protein Estimation Teaching Kit (Quantitative)
U n z i p p i n g G e n e s P r o d u c t I n f o r m a t i o n HiPer® Protein Estimation Teaching Kit (Quantitative) Product Code: HTBC005 Number of experiments that can be performed: 5 Duration of Experiment Protocol Biuret assay: 1 hour Folin – Lowry Assay: 2 hours Bradford assay: 1 hour Storage Instructions: The kit is stable for 12 months from the date of manufacture Store all the kit contents as specified in the brochure 1 Registered Office : Commercial Office 23, Vadhani Industrial Estate,LBS Marg, A-516, Swastik Disha Business Park, Tel: 00-91-22-6147 1919 15 WHO Mumbai - 400 086, India. Via Vadhani Indl. Est., LBS Marg, Fax: 6147 1920, 2500 5764 GMP Tel. : (022) 4017 9797 / 2500 1607 Mumbai - 400 086, India Email : [email protected] CERTIFIED Fax : (022) 2500 2286 Web : www.himedialabs.com The information contained herein is believed to be accurate and complete. However no warranty or guarantee whatsoever is made or is to be implied with respect to such information or with respect to any product, method or apparatus referred to herein Index Sr. No. Contents Page No. 1 Aim 3 2 Introduction 3 3 Materials Required But Not Provided 3 4 Storage 3 5 Biuret Assay 3 Principle Kit contents Important Instructions Procedure Observation and Result Interpretation 6 Folin – Ciocalteau (Lowry) Assay 6 Principle Kit contents Important Instructions Procedure Observation and Result Interpretation 7 Dye Binding (Bradford) Assay 9 Principle Kit contents Important Instructions Procedure Observation and Result Interpretation 8 Troubleshooting Guide 12 2 Aim: To determine the concentration of a protein by three commonly used methods: 1. -
Free of Cost CONTENTS Tender Letter Terms & Conditions with Annexure Check List of the Documents Item Schedule
ESIC E-TENDER ENQUIRY FORM FOR SUPPLY OF LAB REAGENTS, CHEMICAL AND KITS E-Tender Enquiry Form – Free of cost CONTENTS Tender Letter Terms & Conditions with Annexure Check List of the Documents Item Schedule EMPLOYEE’S STATE INSURANCE CORPORATION MEDICAL COLLEGE & HOSPITAL, NH-3 NIT FARIDABAD-121001 LAST DATE OF SUBMISSION OF ONLINE: 09/08/2021 For any further clarifications/queries for e-Procurement Portal, Please contact at: 0129-2970111 CPPP Id for Support / Helpdesk -https://eprocure.gov.in/eprocure/app ESIC Medical College and Hospital NH-3, Faridabad, Haryana- 121001 Tel No: 0129-4156471, Website: www.esic.nic.in E- Tender Enquiry No.134/U/16/30/R.C Lab, Chemical & Kits /2021-Med. Store, Dated:19/07/2021 Dean, ESIC Medical College & Hospital, NH-3, NIT Faridabad invites online e-Tender for the Rate Contract for supply of LAB REAGENTS, CHEMICAL AND KITS, through e- procurement portal- https://eprocure.gov.in/eprocure/app BRIEF OF ESIC RATE CONTRACT 1. It is proposed to enter into a Running Rate Contract with bidder(s)/ firm(s) which fulfill the eligibility criteria approved by Dean, ESIC Medical College & Hospital, NH-3, NIT Faridabad for supply of LAB REAGENTS, CHEMICAL AND KITS/ items enumerated in the schedule annexure B. The eligibility criteria have been given in the terms and conditions as annexure A. Bidder(s)/ Firm(s) intending to participate in the rate contract should first ensure that they fulfill all the eligibility criteria as prescribed under the terms and conditions, otherwise the tenders will be summarily rejected. 2. The Rate Contract will be governed by the terms and conditions enclosed with this Tender Enquiry and no modifications / alterations etc. -
(12) Patent Application Publication (10) Pub. No.: US 2015/0285765 A1 Chung Et Al
US 20150285765A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2015/0285765 A1 Chung et al. (43) Pub. Date: Oct. 8, 2015 (54) ACTIVE TRANSPORT OF CHARGED (52) U.S. Cl. MOLECULES INTO, WITHIN, AND/OR FROM CPC. G0IN 27/44756 (2013.01); G0IN 27/44704 CHARGED MATRICES (2013.01); G0IN 27/44708 (2013.01) (71) Applicant: Massachusetts Institute of Technology, Cambridge, MA (US) (57) ABSTRACT (72) Inventors: Kwanghun Chung, Cambridge, MA (US); Sung-Yon Kim, Cambridge, MA Articles and methods for the active transport of molecules (US); Kimberly Ohn, Boston, MA (US); into, within, and/or from a matrix are generally described. In Evan Murray, Cambridge, MA (US); some embodiments, an electric field may be used to alter the Jae Hun Cho, Cambridge, MA (US) position of the molecule with respect to the matrix. The elec tric field may be used to move the molecule to a new location (73) Assignee: Massachusetts Institute of Technology, within the matrix, remove the molecule from the matrix, or Cambridge, MA (US) infuse the molecule into the matrix. For instance, the electric field may be used to move a molecule having a binding (21) Appl. No.: 14/678,660 partner within the matrix into or away from the vicinity of the binding partner. In some embodiments, the position of the (22) Filed: Apr. 3, 2015 molecule may be altered by exposing the molecule to an electrodynamic field. In some Such embodiments, the mol Related U.S. Application Data ecule exposed to the dynamic electric field may have (60) Provisional application No. -
(12) United States Patent (10) Patent No.: US 9,636.405 B2 Tamarkin Et Al
USOO9636405B2 (12) United States Patent (10) Patent No.: US 9,636.405 B2 Tamarkin et al. (45) Date of Patent: May 2, 2017 (54) FOAMABLE VEHICLE AND (56) References Cited PHARMACEUTICAL COMPOSITIONS U.S. PATENT DOCUMENTS THEREOF M (71) Applicant: Foamix Pharmaceuticals Ltd., 1,159,250 A 1 1/1915 Moulton Rehovot (IL) 1,666,684 A 4, 1928 Carstens 1924,972 A 8, 1933 Beckert (72) Inventors: Dov Tamarkin, Maccabim (IL); Doron 2,085,733. A T. 1937 Bird Friedman, Karmei Yosef (IL); Meir 33 A 1683 Sk Eini, Ness Ziona (IL); Alex Besonov, 2,586.287- 4 A 2/1952 AppersonO Rehovot (IL) 2,617,754. A 1 1/1952 Neely 2,767,712 A 10, 1956 Waterman (73) Assignee: EMY PHARMACEUTICALs 2.968,628 A 1/1961 Reed ... Rehovot (IL) 3,004,894. A 10/1961 Johnson et al. (*) Notice: Subject to any disclaimer, the term of this 3,062,715. A 1 1/1962 Reese et al. tent is extended or adiusted under 35 3,067,784. A 12/1962 Gorman pa 3,092.255. A 6/1963 Hohman U.S.C. 154(b) by 37 days. 3,092,555 A 6/1963 Horn 3,141,821 A 7, 1964 Compeau (21) Appl. No.: 13/793,893 3,142,420 A 7/1964 Gawthrop (22) Filed: Mar. 11, 2013 3,144,386 A 8/1964 Brightenback O O 3,149,543 A 9/1964 Naab (65) Prior Publication Data 3,154,075 A 10, 1964 Weckesser US 2013/0189193 A1 Jul 25, 2013 3,178,352.